Usage of Nucleo CMP Forte in the combined treatment of patients has more expressed positive influence on problems with walking. Administration of two nucleotides, cytosine monophosphate (CMP) and uridine. Significance was set at P0.05) and 33.3% (χ 2=6.171, P0.05) and 50% (χ 2=2.859, P>0.05) of ones respectively, pain/discomfort bothered less than 25% (χ 2=4.267, P<0.05) patients of the group A and 33.3% (χ 2=6.171, P<0.05) of the group B, anxiety/depression decreased in 58.3% (χ 2=6.063, P<0.05) and 66.7% (χ 2=6.954, P<0.05), respectively.Ĭonclusion: Patients of both groups noted the positive effect of treatment. Nucleo Cmp Forte capsule is used for Nucleoside reverse transcriptase inhibitors-related mitochondrial toxicity and other conditions. We used non-parametric test χ 2 to evaluate efficacy of therapy. Patients filled questionnaire of life quality EQ-5D-3L (Ukraine 2004, EuroQol) on the first and tenth day of treatment. They were compared into two groups: A 30 patients received standard.
Methods: It was examined 59 (4179 years old) patients with type 2 DM and DPNP. Researchers are the persons who are responsible for the scientific research. They were compared into two groups: A 30 patients received standard treatment, B 29 diabetics additionally were taken Nucleo CMP Forte (1 capsule three times a day). The aim: To evaluate the efficacy of Nucleo CMP Forte (Cytidine 5’- disodium monophosphate and Uridine 5’- trisodium triphosphate) in the combined treatment of patients with DPNP. Nucleo CMP Forte pharmaceutical companies: Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug. Methods: It was examined 59 (41≧9 years old) patients with type 2 DM and DPNP. The aim: To evaluate the efficacy of Nucleo CMP Forte (Cytidine 5- disodium monophosphate and Uridine 5- trisodium triphosphate) in the combined treatment of patients with DPNP. New medications in DPNP have to be studied. Introduction: The protocols of medical care of diabetic peripheral neuropathy (DPNP) are developed but positive effect cannot be achieved in all patients.